AzTrials
AzTrials

Plasma Concentration of AntibioticsNCT02058979

Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery

A study testing BOLUS INFUSION (Ancef) and CONTINUOUS INFUSION (Ancef) in people with Plasma Concentration of Antibiotics, run by University of Virginia at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Abstract The administration of an antibiotic preoperatively is an important intervention that helps to reduce the risk of post-operative health-care associated infections (HCAI). These include urinary tract, surgical site and blood stream infection. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Plasma Concentration of Antibiotics
What is being tested?
BOLUS INFUSION (Ancef) and CONTINUOUS INFUSION (Ancef)
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteUnited States
Study dates
Nov 2014to Jun 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age > 18 years
  • Elective abdominal and orthopedic surgery
  • A patent arterial line
  • A patent IV line
  • Must be able to read and speak English

Who cannot join

  • Subjects unable to give informed consent.
  • Allergy to cefazolin
  • Cognitively Impared
  • Prisoners
  • Pregnant females (self reported)
  • History of coagulopathy
Show all 9Show fewer
  • Subjects presenting for emergency abdominal surgery
  • Creatinine clearance < 30 ml/min
  • Received cefazolin within 72 hours prior to surgery

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Virginia

    Charlottesville, Virginia, 22910-0710

Other trials in United States

About this study

Abstract The administration of an antibiotic preoperatively is an important intervention that helps to reduce the risk of post-operative health-care associated infections (HCAI). These include urinary tract, surgical site and blood stream infection. Based on the current Surgical Infection Prevention Project, (SCIP) recommendations, the choice of the antibiotic is based on the nature and site of the surgery and the presence of a β-lactam allergy (Table 1).

Currently, the antibiotic treatment for preventing surgical infections is administered as a single bolus an hour before surgery, and every four hours after the initial dose. This presents a concentration profile that has a high concentration after the bolus, but decays as the kidneys remove the antibiotics. In this present study, investigators would like to compare this traditional method of delivery to a constant infusion model that would sustain a constant level of antibiotics that is defined by the difference between the rate of infusion and rate of clearance.

Read the detailed description

The current incidence of post-operative surgical infections varies between 6% for patients undergoing non-cardiac surgery to greater than 30% in high-risk surgery. 1 The administration of an antibiotic preoperatively is an important intervention that helps to reduce the risk of post-operative health-care associated infections (HCAI). These include urinary tract, surgical site and blood stream infection. Based on the current Surgical Infection Prevention Project, (SCIP) recommendations, the choice of the antibiotic is based on the nature and site of the surgery and the presence of a β-lactam allergy (Table 2). The antibiotic of choice for perioperative prophylaxis remains first and second generation cephalosporin. These drugs have a broad range of antimicrobial activity against common skin pathogens and have an excellent safety profile.

Based on current recommendations, the cephalosporin is administered 1 hour prior to incision.1 Timing is critical, as both early and late administration of the antibiotic is associated with an increase risk of HCAI. Additional doses of the cephalosporin are administered at pre-set intervals based on the duration of the surgery in an attempt to maintain antibiotic concentrations at a desired level.

Antibiotics can be classified into two broad classes, based on their bacterial killing characteristics. Antibiotics with concentration-dependent killing characteristics require a high ratio between the peak concentration and the minimum inhibitory concentration (MIC) of the pathogen, during the dosing interval. Therefore large infrequent doses of these antibiotics will result in optimal antibacterial activity.

In contrast β-lactam antibiotics, like cephalosporins, demonstrate time-dependent pharmacokinetics. This means that effective microbiological activity only occurs if the unbound (or free) plasma concentration of the drug is above the MIC for a specified time period. In infection models, bacteriostatic and bacteriocidical activity occurs when antibiotic concentrations are maintained above the MIC for 35-40% and 60-70% of the dosing interval respectively. However, in surgical prophylaxis, it is preferred that antibiotic concentrations are maintained above the MIC of the likely pathogen/s for the entire duration of the procedure. Therefore more frequent dosing or use of extended or continuous infusion of these drugs will better maintain the pharmacokinetic goals. Recent studies have shown that plasma levels of β-lactam antibiotics fall below the MIC 1-2 hours after the initial bolus dose in both normal and obese patients.2, 3 Even with appropriate re-dosing of the β-lactam antibiotic, there are times when the plasma concentration of the drug is below the MIC. The combination of sub-MIC plasma drug level and high bacteremic load can potentially increase the risk of developing a post-operative HCAI. It follows that to effectively prevent microbiological activity in the perioperative period the β-lactam antibiotic must remain above the MIC during the entire operative period. This is of particular importance in patients undergoing major abdominal surgery where the risk of perioperative surgical site infection (including superficial, deep and organ specific infection) is 13.1%. The aim of this study is to compare the pharmacokinetics of bolus and continuous cefazolin infusion during major abdominal surgery.

Hypothesis to be Tested Hypothesis A continuous infusion of cefazolin maintains the unbound plasma concentration above Minimum Inhibitory Concentration (MIC) for the duration of the operative procedure better than the traditional bolus administration at every four hours.

Specific Aims

  1. Compare the pharmacokinetics of a bolus versus continuous cefazolin (Ansef) infusion in major surgery
  2. Preliminary studies

There are 2 studies in the abdominal surgery population. The study by Troconiz et al studies the pharmacokinetics of a bolus dose of cefoxitin.3 The study by Suffoleta studied a postoperative continuous infusion in the postoperative colorectal group.4

  1. Experimental design and methods (including data analysis)

Informed consent for the study will be obtained in the PETC (Pre-anesthesia Clinic) prior to surgery.

Induction and maintenance of anesthesia will be at the discretion of the attending anesthesiologist. Intraoperative analgesia will be provided at the discretion of the attending anesthesiologist and may include intravenous narcotics and/or intrathecal morphine.

Being tested
BOLUS INFUSION (Ancef), CONTINUOUS INFUSION (Ancef)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BOLUS INFUSION (Ancef)Drug

    Also called ANCEF Bolus Infusion of antibiotics

    Bolus Infusion of antibiotics

  • CONTINUOUS INFUSION (Ancef)Drug

    Also called Continuous Infusion of ANCEF with infusion pump

    Continuous Infusion of ANCEF with infusion pump

Study groups in NCT02058979
Study groupRoleWhat they receive
BOLUS INFUSIONActive comparatorBolus infusion of antibiotics
Receives: Drug: BOLUS INFUSION (Ancef)
CONTINUOUS INFUSIONExperimentalContinuous infusion of antibiotics by way of infusion pump
Receives: Drug: CONTINUOUS INFUSION (Ancef)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Plasma Concentration of Antibiotics

    Plasma concentration of antibiotics during surgery

    Measured: 1 Day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Feb 2014 (estimated)
  2. Study startNov 2014
  3. Primary completionJun 2016
  4. Study completionJun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02058979
Sponsor's protocol ID
17266
Status last verified
Oct 2016
First submitted
6 Feb 2014
Last updated
26 Oct 2016
Results posted
No
Data monitoring committee
No

Publications

  • Suffoletta TJ, Jennings HR, Oh JJ, Stephens D, Poe KL. Continuous versus intermittent infusion of prophylactic cefoxitin after colorectal surgery: a pilot study. Pharmacotherapy. 2008 Sep;28(9):1133-9. doi: 10.1592/phco.28.9.1133.

    PubMed 18752384
  • Toma O, Suntrup P, Stefanescu A, London A, Mutch M, Kharasch E. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. Anesth Analg. 2011 Oct;113(4):730-7. doi: 10.1213/ANE.0b013e31821fff74. Epub 2011 Jun 3.

    PubMed 21642605
  • Isla A, Troconiz IF, de Tejada IL, Vazquez S, Canut A, Lopez JM, Solinis MA, Rodriguez Gascon A. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol. 2012 May;68(5):735-45. doi: 10.1007/s00228-011-1206-1. Epub 2012 Jan 15.

    PubMed 22246211
  • Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis. 2006 Aug 1;43(3):322-30. doi: 10.1086/505220. Epub 2006 Jun 16.

    PubMed 16804848
  • Naik BI, Roger C, Ikeda K, Todorovic MS, Wallis SC, Lipman J, Roberts JA. Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. Br J Anaesth. 2017 Jun 1;118(6):876-882. doi: 10.1093/bja/aex026.

    PubMed 28505360

Questions about this trial

What is this clinical trial studying?

A study testing BOLUS INFUSION (Ancef) and CONTINUOUS INFUSION (Ancef) in people with Plasma Concentration of Antibiotics, run by University of Virginia at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Plasma Concentration of Antibiotics (time frame: 1 Day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02058979, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in